Semax 10 mg

Semax's 30 mg vial is $139.99, $74.00 more than this 10 mg Semax one. Three of these cost $188.07, so the bigger vial saves $48.08.

Per milligram, Semax 10 mg works out to about $6.60 — $65.99 across 10 mg. The 30 mg Semax vial works out to about $4.67 a milligram.

A 10 mg Semax vial contains ten thousand micrograms. Taken to two millilitres, each 0.1 mL draw measures five hundred micrograms, giving twenty of them; halve the draw and it gives forty of two hundred and fifty.

The 10 mg Semax vial is dearer per milligram because its fixed costs — container, closure, labelling, handling and postage — do not change with fill weight, so a third of the powder carries the same overhead. Both Semax listings show their own rate.

The 10 mg Semax vial suits a first evaluation or a short bench series where holding a large quantity of an unfamiliar compound is not wanted. It also suits a schedule where each stage begins with its own unopened vial.

Semax 10 mg is $65.99 a vial (ARP-SEMAX-10). Two 10 mg vials come to $125.38 after Semax's 5% multi-vial discount, $6.60 off.

Not on its own. Semax 10 mg is $65.99, $133.01 under $199. Semax clears it with four 10 mg vials. Semax's 30 mg vial falls short too.

$78.98 delivered in Australia. Semax 10 mg is $65.99, plus $12.99 for ARP-SEMAX-10 by Standard tracked post. Express Post makes ARP-SEMAX-10 $82.98.

Five vials of Semax. At $65.99 each, five 10 mg vials make $329.95 — past $299, so ARP-SEMAX-10 ships free by Express Post, costing $313.45.

Semax is available from Australian Research Peptides and not from Chemist Warehouse, which cannot sell it. Semax is a registered medicine in Russia and in no other market, so there is no Australian registration for a pharmacist here to dispense against. ARP supplies it as a research compound in two vial sizes, under Nootropic Peptides.

Semax in solution is refrigerated at 2 to 8 degrees and given a life of eight weeks to twelve by Australian Research Peptides' published condition. Semax opens on a methionine — MEHFPGP places the most oxidation-prone residue first, at an unblocked N-terminus — so light and dissolved air deserve as much attention as the calendar. The 30 mg vial is likelier to outlast that window.

Semax needs bacteriostatic water because the vial contains dry peptide and nothing wet. Australian Research Peptides keeps that water in Lab Supplies under its own listing, never bundled into the Semax entry. Diluent is the standard term for whatever a dry compound dissolves into. Semax comes in two vial sizes, both equally dry, so each needs its own.

Semax at 10 mg/mL needs 1 mL; Semax at 5 mg/mL needs 2 mL. ARP-SEMAX-10 is 10 mg dry: water sets ARP-SEMAX-10 strength, never its mass.

Published work on Semax centres on gene expression in brain tissue. Dmitrieva 2010 found Semax raised transcription of the genes for BDNF, nerve growth factor and their Trk receptors in rats. Those proteins keep neurons alive and maintain their connections. Dolotov 2006 gave rats a single intranasal dose of 50 micrograms per kilogram and saw hippocampal BDNF protein rise 1.4-fold. Sudarkina 2021 measured more active CREB, a gene switch, in damaged tissue.

Research on Semax is almost entirely in animals, and mostly about the brain after injury. Dmitrieva 2010 found that in a rat stroke model Semax activated transcription of Bdnf, Ngf and Nt-3 and their receptors. Sudarkina 2021 reported active JNK down more than 1.5-fold and Fos mRNA down 2.6-fold in ischaemic rat tissue. Eremin 2005 measured 5-HIAA, a serotonin breakdown product, up 25 percent in mouse striatum within two hours.

Australian Research Peptides supplies Semax as one freeze-dried solid in a sealed vial, not as a liquid nasal product. That solid is the chain MEHFPGP, at the milligram weight printed on the label. The powder runs white to off-white inside sealed, tamper-evident glass. There is no filler, no carrier, no second peptide and no liquid. Four of the seven amino acids reproduce part of adrenocorticotropic hormone, and the closing proline-glycine-proline is added in the lab.

Animal studies gave Semax into the nose or by injection into the abdomen. Dolotov 2006 used one intranasal dose of 50 micrograms per kilogram in rats. Sudarkina 2021 and Medvedeva 2014 both injected Wistar rats with 100 micrograms per kilogram, repeated over the first hours after an induced stroke. Eremin 2005 used 0.15 milligrams per kilogram by injection in C57BL mice. Every amount quoted for Semax comes from an animal study.

Semax survives in blood only briefly, though no clean half-life figure has been printed. Potaman's 1991 study in Biochemical and Biophysical Research Communications followed it through rat serum by chromatography, finding aminopeptidase stripping the first two residues away. The intermediates accumulated in comparable amounts, and those authors argued such fragments may carry part of the parent's activity, so the original chain disappearing is not the end of the account.

Semax is built from seven amino acids in one chain, which makes it a heptapeptide. In order they are Met-Glu-His-Phe-Pro-Gly-Pro, shortened to MEHFPGP. Met-Glu-His-Phe is a stretch of adrenocorticotropic hormone, positions four through seven. The last three are a synthetic addition the hormone itself does not have. The count of seven belongs to Semax itself, so both vial sizes contain the identical chain.

Semax has more human data behind it than most research peptides, because it has been a registered product in Russia for decades and its literature includes clinical studies in stroke and cognitive settings. That literature is largely Russian-language and has not been replicated in large Western trials, which is the main reason it remains unfamiliar elsewhere.

Semax's published studies sampled effects over hours to days rather than months, and the acute stroke work administered it over a defined short course. There is no long-run controlled trial establishing what happens over weeks of continuous use, so a timescale in months is not something the evidence supports either way.

Semax has decades of Russian clinical use behind it, and that literature describes courses with a defined endpoint rather than indefinite use, yet published observation after a course concludes is thin. No withdrawal syndrome is reported in it. Since that record has never been assessed outside Russia and large independent trials have not repeated it, it makes weak ground for confident statements about stopping.

Semax's registered form in Russia is an intranasal solution, and its clinical record describes it as well tolerated with local nasal irritation the main issue noted. No Western regulator has reviewed that record, and none of it describes the lyophilised research powder Australian Research Peptides supplies or any route other than nasal.

Semax comes in two quantities and they look markedly different. Ten milligrams leaves a faint dusting easily read as an empty container; thirty milligrams is three times as much solid and forms a properly visible cake. Neither holds a bulking agent, so what sits inside the glass is peptide alone. Comparing the two strengths explains most confusion about the smaller one.

Store the sealed Semax vial frozen, dry and out of the light. GenScript flags cysteine, methionine and tryptophan as prone to oxidation, and Semax opens with a methionine, which is why light and air matter. Bachem keeps freeze-dried peptides below minus 15 degrees Celsius in a closed container, and GenScript's own figure is minus 20, away from bright light. Warm a frozen vial fully before you break the seal, so moisture does not condense inside. Peptide in solution is far less stable than the dry powder.

Most cloudy Semax reports come down to bubbles worked in during mixing, and they lift out within minutes of the vial being set down. The thirty-milligram strength dissolves more slowly than the ten, having three times as much material to take up, so patience beats extra agitation. Once warmed and rested a proper preparation is clear; lasting milkiness or floating specks are not normal.

Semax is also known as ACTH(4-7)PGP, as MEHFPGP in single-letter code, and by its written sequence Met-Glu-His-Phe-Pro-Gly-Pro; some papers file it as an analogue of ACTH(4-10). Replacing the last three residues with Pro-Gly-Pro is what removes the corticotropic activity, so it is an analogue rather than a piece of ACTH itself. N-Acetyl Semax and the amidated version are related molecules with their own database records, not alternative names. Whichever term you typed, the vial ships from Australian Research Peptides, warehoused locally and HPLC-tested, with the CoA library showing where a certificate is already published.

Plain Semax is not the same as N-Acetyl Semax Amidate. Australian Research Peptides supplies plain Semax, unmodified at both ends of the chain, with a free amino group at one end and a free acid at the other. N-Acetyl Semax Amidate carries an acetyl group at one end and an amide at the other, changes intended to alter stability. It is a different molecule with a different molecular formula, held as a separate record in the public databases, and suppliers do not always make the distinction clear. ARP states which of the two it supplies in its published specifications.

Semax and Selank come from the same Russian research programme but derive from different parents — Semax from an ACTH fragment, Selank from tuftsin — and their published literatures point in different directions, Semax toward cognitive and neuroprotective settings and Selank toward anxiety. They are complementary rather than competing, which is why researchers frequently hold both.

Semax is sold in Australia as a laboratory research chemical, and Australian Research Peptides supplies it on that basis only. ARP makes no medical claim for Semax anywhere. Australia sorts medicines and poisons into schedules under the Poisons Standard, administered by the TGA. Anything to do with use in a person sits outside what ARP supplies Semax for.

Semax has never been approved in the United States. It is approved somewhere, however: Russia's health ministry registered it as a medicine in 1994, in an intranasal form. A registration granted in one country is not a worldwide licence, and no Western agency has assessed the Russian-language clinical record standing behind it. Freeze-dried research powder is not that registered product in any case.

Semax has no listing of its own in any prohibited category. Whether the residual S0 heading reaches it turns on one point: Russia's health ministry registered Semax as a medicine in 1994, and S0 excludes anything a government regulator has approved somewhere. Whether an anti-doping panel accepts a Russian registration is untested, so Australian athletes should ask Sport Integrity Australia.